Search results
Results From The WOW.Com Content Network
4,4′-Dihydroxybenzophenone is prepared by the rearrangement of p-hydroxyphenylbenzoate: HOC 6 H 4 CO 2 C 6 H 5 → (HOC 6 H 4) 2 CO. Alternatively, p-hydroxybenzoic acid can be converted to p-acetoxybenzoyl chloride. This acid chloride reacts with phenol to give, after deacetylation, 4,4′-dihydroxybenzophenone.
This page was last edited on 21 October 2024, at 09:56 (UTC).; Text is available under the Creative Commons Attribution-ShareAlike 4.0 License; additional terms may apply.
Sivifene (INN, USAN; developmental code name A-007) is a small-molecule antineoplastic agent and immunomodulator that was under development in the 2000s by Tigris Pharmaceuticals (now Kirax Corporation) as a topical treatment for cutaneous cancer metastases.
The scientists analyzed blood, urine, feces, and tissue samples and found three metabolites: 2,4-dihydroxybenzophenone (DHB), 2,2-dihydroxy-4-methoxybenzophenone (DHMB) and 2,3,4-trihydroxybenzophenone (THB). [28] [29] To form DHB the methoxy functional group undergoes O-dealkylation; to form THB the same ring is hydroxylated. [27]
There are three structural isomers: 1,2-dihydroxybenzene (the ortho isomer) is commonly known as catechol, 1,3-dihydroxybenzene (the meta isomer) is commonly known as resorcinol, and 1,4-dihydroxybenzene (the para isomer) is commonly known as hydroquinone. [1]
This strong market position generates substantial cash flows that support shareholder returns. Turning to the specifics, the pharmaceutical giant offers investors a 4.3% dividend yield backed by a ...
430 N⋅m (317 lb⋅ft) at 1,700–3,600 rpm 2023–present Lexus NX 350: TAZA25 205 kW (275 hp; 279 PS) at 6,000 rpm 430 N⋅m (317 lb⋅ft) at 1,700–3,600 rpm 2021–present Lexus RX 350: TALA10 TALA15 2022–present Lexus TX 350: 2022–present Lexus RX 500h: TALH17 202 kW (271 hp; 275 PS) at 6,000 rpm
After introducing medically assisted treatment in 2013, Seppala saw Hazelden’s dropout rate for opiate addicts in the new revamped program drop dramatically. Current data, which covers between January 1, 2013 and July 1, 2014, shows a dropout rate of 7.5 percent compared with the rate of 22 percent for the opioid addicts not in the program.